{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:01:11Z","timestamp":1761854471220,"version":"build-2065373602"},"reference-count":19,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.medcli.2019.05.009","type":"journal-article","created":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T17:18:50Z","timestamp":1563988730000},"page":"131-133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tratamiento actual de las neoplasias mieloproliferativas: frente a tres escenarios"],"prefix":"10.1016","volume":"154","author":[{"given":"Blanca","family":"Xicoy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lurdes","family":"Zamora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2019.05.009_bib0100","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/17474086.2014.966679","article-title":"Generics in chronic myeloid leukemia: current arguments for and against and the established evidence","volume":"7","author":"Soysal","year":"2014","journal-title":"Expert Rev Hematol."},{"key":"10.1016\/j.medcli.2019.05.009_bib0105","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"EURO-SKI investigators Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medcli.2019.05.009_bib0110","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1182\/blood.V126.23.345.345","article-title":"Long-Term Follow-up of the French 1 Stop Imatinib Study (STIM1) in Chronic Myeloid Leukemia Patients","volume":"126","author":"Etienne","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2019.05.009_bib0115","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","article-title":"Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1","volume":"61","author":"Schoepfer","year":"2018","journal-title":"J Med Chem."},{"key":"10.1016\/j.medcli.2019.05.009_bib0120","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00277-014-2231-9","article-title":"Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment","volume":"94","author":"Breccia","year":"2015","journal-title":"Ann Hematol."},{"key":"10.1016\/j.medcli.2019.05.009_bib0125","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/asheducation-2018.1.177","article-title":"We do still transplant CML don\u2019t we?","author":"Craddock","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program."},{"key":"10.1016\/j.medcli.2019.05.009_bib0130","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00432-018-2604-x","article-title":"Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENEST freedom study","volume":"144","author":"Ross","year":"2018","journal-title":"J Cancer Res Clin Oncol."},{"key":"10.1016\/j.medcli.2019.05.009_bib0135","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1002\/cncr.30885","article-title":"French Intergroup for Chronic Myeloid Leukemias Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia","volume":"123","author":"Legros","year":"2017","journal-title":"Cancer."},{"key":"10.1016\/j.medcli.2019.05.009_bib0140","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2019.05.009_bib0145","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2019.05.009_bib0150","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-017-0527-7","article-title":"Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses","volume":"29","author":"Verstovsek","year":"2017","journal-title":"J Hematol Oncol."},{"key":"10.1016\/j.medcli.2019.05.009_bib0155","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs Robyn M","volume":"30","author":"Dueck","year":"2012","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2019.05.009_bib0160","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2018-99-118348","article-title":"Secreted Mutant Calreticulins As Rogue Cytokines Trigger Thrombopoietin Receptor Activation Specifically in CALR Mutated Cells: Perspectives for MPN Therapy","volume":"132","author":"Pecquet","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2019.05.009_bib0165","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/ajh.25303","article-title":"Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management","volume":"94","author":"Tefferi","year":"2019","journal-title":"Am J Hematol."},{"key":"10.1016\/j.medcli.2019.05.009_bib0170","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3324\/haematol.2016.143644","article-title":"Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial","volume":"101","author":"Verstovsek","year":"2016","journal-title":"Haematologica."},{"key":"10.1016\/j.medcli.2019.05.009_bib0175","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1007\/s00277-018-3365-y","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial","volume":"97","author":"Griesshammer","year":"2018","journal-title":"Ann Hematol."},{"issue":"suppl 1","key":"10.1016\/j.medcli.2019.05.009_bib0180","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2018-99-118715","article-title":"Evidence for Superior Efficacy and Disease Modification after Three Years of Prospective Randomized Controlled Treatment of Polycythemia Vera Patients with Ropeginterferon Alfa-2b Vs HU\/BAT. Hematology Am Soc Hematol Educ Program","volume":"132","author":"Gisslinger","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.medcli.2019.05.009_bib0185","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2018-99-112518","article-title":"The Specific and Synergistic Targeting of JAK2V617F Cells By Interferon Alpha and Arsenic","volume":"132","author":"Maslah","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2019.05.009_bib0190","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/leu.2015.45","article-title":"Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia","volume":"29","author":"Burchert","year":"2015","journal-title":"Leukemia."}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775319304142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775319304142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:50:25Z","timestamp":1758419425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775319304142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0025775319304142"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2019.05.009","relation":{},"ISSN":["0025-7753"],"issn-type":[{"type":"print","value":"0025-7753"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tratamiento actual de las neoplasias mieloproliferativas: frente a tres escenarios","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2019.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}